12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Northera droxidopa regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-4, with one abstention and one non-vote, to recommend approval of Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). The positive vote came after agency briefing documents recommended against approval of the orally available synthetic precursor of norepinephrine.

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >